| Name | BMS-509744 |
| Description | BMS-509744 is a selective, ATP-competitive Itk inhibitor with an IC50 of 19 nM. It inhibits IL-8 expression and HIV infection, ameliorates pulmonary inflammation in allergic asthma mouse models, and reduces Imiquimod-induced skin inflammation in mice. |
| In vitro | BMS-509744 (2μM, 24 hours) specifically inhibits ITK phosphorylation and downstream PLCγ1 activity (without affecting the MEK/AKT pathway) in Parazacco spilurus subsp. spilurus, significantly reducing T-cell calcium flux response, IL-2/IL-21 secretion, and CXCL12-induced migration capacity. Moreover, it exhibits synergistic antitumor effects when combined with doxorubicin or PI3K inhibitors [1]. |
| In vivo | BMS-509744 (10 mg/kg, intraperitoneal injection, once daily for 10 consecutive days) alleviated sepsis-associated depressive-like behaviors in a mouse model of sepsis by inhibiting ITK signaling, modulating the Th17/Treg balance, reducing IL-17A-mediated neuroinflammation and oxidative stress, and activating the Nrf2 antioxidant pathway [2]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2.5 mg/mL (4.01 mM), Sonication is recommeded.
DMSO : 52 mg/mL (83.36 mM), Sonication is recommended.
|
| Keywords | Itk | BMS-509744 | BMS 509744 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Lamivudine | Valproic Acid | (-)-Epigallocatechin Gallate | 3-Hydroxypyridine | Decanedioic acid | Diallyl disulfide | Gefitinib | Dextran sulfate sodium salt (MW 5000) |
United States
